Research programme: oligonucleotide-based antimicrobials - Procarta Biosystems
Alternative Names: PRO 202Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator Procarta Biosystems
- Class Anti-infectives; Antibacterials; Oligonucleotides; Small molecules
- Mechanism of Action Gene expression inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Intra-abdominal infections; Urinary tract infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Intra-abdominal-infections(Complicated) in United Kingdom (PO)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Urinary-tract-infections(Complicated) in United Kingdom (PO)
- 24 Jan 2019 Research programme: oligonucleotide-based antimicrobials - Procarta Biosystems is available for licensing as of 24 Jan 2019. https://www.procartabio.com/